UMARY- USA.COM Issues Voluntary Nationwide Recall of UNAVY ACIDIO
HIALURONICO Caplets and UMOVY ACIDIO HIALURONICO Caplets Due to the Presence
of Undeclared Drug Ingredients Dexamethasone, Diclofenac and Omeprazole
Company Contact:
Name: Hugo Ramirez
Phone Number: 520-342-7385
FOR IMMEDIATE RELEASE – Date: May 21 2025, Nogales, AZ, UMARY USA is
voluntarily recalling all lots of Unavy Acidio Hialuronico (30 caplets/850 mg) and Umovy
Acidio Hialuronico (30 caplets/850 mg), to the consumer level. FDA laboratory analysis
confirmed that these products are tainted with the drug ingredients Diclofenac, Dexamethasone
and Omeprazole. Products containing Diclofenac, Dexamethasone or Omeprazole cannot be
marketed as dietary supplements. UNAVY ACIDIO HIALURONICO and UMOVY ACIDIO
HIALURONICO are unapproved new drugs for which safety and efficacy have not been
established and, therefore, subject to recall.
Risk Statement: Dexamethasone is a corticosteroid commonly used to treat inflammatory
conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high
blood sugar levels, muscle injuries, psychiatric problems, and lead to cardiovascular events.
When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the
adrenal gland (a disorder in which the adrenal glands do not produce enough hormones) and
adverse consequences can range from limited adverse consequences to death. Additionally,
abrupt discontinuation can cause withdrawal symptoms. Diclofenac is a non-steroidal anti-
inflammatory drug (commonly referred to as NSAIDs). Consumption of undeclared diclofenac
could result in serious adverse events that include cardiovascular, gastrointestinal, renal, and
anaphylaxis in patients taking concomitant NSAIDs and/or anticoagulants, in those who have
allergies to diclofenac, or those with underlying illnesses. Omeprazole is a proton pump inhibitor
(commonly referred to as PPI) used to treat gastric (stomach) acid-related disorders.
Consumption of undeclared omeprazole may mask stomach issues such as erosions, ulcers, and
stomach cancer. Consumption of undeclared dexamethasone, diclofenac, and omeprazole can
also interact with other medications and cause serious side effects. Umary- usa.com has not
received any reports of adverse events related to this recall.
These products are marketed as dietary supplements for joint pain and arthritis. UNAVY
ACIDIO HIALURONICO is packaged in a white plastic container with a black background
label, and white and yellow writing on it. The bottle has 30 caplets/ 850 mg. The affected
product includes all lots and expiration dates. UMOVY ACIDIO HIALURONICO is a black
plastic bottle with a black label with white and blue lettering on the label. The bottle has 30
caplets/ 850mg. The affected product includes all lots and expiration dates. Product was
distributed Nationwide via internet, exclusively via umary-usa.com .
Umary-usa.com is notifying its distributors and customers by Press release and email and is
arranging for return and refund of all recalled products. Consumers who have any of these
products, should immediately work with their physician and/or health care provider to safely
discontinue use of these products..Consumers with questions regarding this recall can contact
umary-usa.com at umaryusa2025@gmail.com , available seven days a week, 24 hours a day.
Consumers should contact their physician or healthcare provider if they have experienced any
problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported
to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by
fax.
Complete and submit the report Online: www.fda.gov/medwatch/report.htm 1
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm 2 or call 1-
800-332-1088 to request a reporting form, then complete and return to the address on the
pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
